At the pulse of heart disease

We are pioneers in the discovery and development of non-coding RNA-based therapeutics designed to address the root causes of heart disease.

A plastic red heart in an indicated rib cage, on a light background

Mode of Action

The video illustrates how CDR132L operates in cardiac cells to reverse adverse cardiac remodeling and restore normal cellular functions.

CDR132L is currently being evaluated in HF-REVERT Phase 2 Clinical Study in heart failure patients after myocardial infarction.


The 4th Annual Conference on Oligonucleotide Therapeutics and Delivery
Dr. Claudia Ulbrich interviewed by Philip Hemme in the Podcast

Insight into the history of Cardior, its lead compound CDR132L and the €1B acquisition by Novo Nordisk in an hour-long conversation with Philip Hemme in - Europe’s Biotech Podcast.

Acquisition of Cardior Pharmaceuticals by Novo Nordisk A/S officially completed

The transaction on the acquisition of Cardior Pharmaceuticals by Novo Nordisk A/S received all regulatory approvals and is officially completed. As of May 2, 2024, Cardior Pharmaceuticals is a fully owned subsidiary of Novo Nordisk A/S. The transition process is now in progress. Novo Nordisk plans to initiate a second phase 2 trial to investigate Cardior’s lead compound in a chronic heart failure population and advance it further towards market approval.

Novo Nordisk logo
Effective 2 May 2024,
Cardior Pharmaceuticals is a wholly-owned subsidiary
of Novo Nordisk Region Europe A/S

This will close in 0 seconds